Indications
- Hyperlipidemia: FDA-approved
- Osler Trial
Pharmacology
- Human PCSK9 Monoclonal Antibody: acts to
Metabolism
- xxxx
Administration
- Cost: $14,100/yr
Dose Adjustment
- Hepatic:
- Renal:
Adverse Effects
Other Adverse Effects
- xxx
- xxx
- xxx
References
- xxxx